Home/News/Semaglutide

Metabolic Research

GLP-1 Agonist

Semaglutide (Ozempic/Wegovy): The Full Deep Dive

Semaglutide is the GLP-1 receptor agonist that turned incretin science into a cultural phenomenon. Engineered for once-weekly dosing, it went on to prove benefit not just for blood sugar and weight, but for the heart and kidneys too. This article traces its history from the discovery of GLP-1, through the SUSTAIN, STEP, and SELECT trials, its FDA approval timeline, exactly how it works, and the downstream effects we know and are still studying.

Educational content. Semaglutide is an FDA-approved prescription medicine (Ozempic, Wegovy, Rybelsus) that must be prescribed and monitored by a licensed clinician. This article explains the science and is not medical advice or an endorsement of any product, including unregulated 'research' material sold under this name.

Brand names

Ozempic, Wegovy, Rybelsus

Drug class

GLP-1 receptor agonist

FDA approved

Yes — T2D 2017, obesity 2021

Route

Weekly injection / daily oral

History & Discovery

1980s–90s

The incretin discovery

Scientists discovered GLP-1 (glucagon-like peptide-1), a gut hormone that boosts insulin after meals. Its problem: native GLP-1 is destroyed within minutes by the enzyme DPP-4, making it useless as a drug in raw form.

2000s

From exenatide to liraglutide

The first GLP-1 drugs (exenatide, then Novo Nordisk's daily liraglutide/Victoza and weight-loss Saxenda) proved the class worked. Novo then engineered a longer-acting successor by modifying the peptide backbone and attaching a fatty-acid chain that binds albumin.

2012–2017

Semaglutide is developed

Semaglutide's acylation and amino-acid substitutions resist DPP-4 degradation and extend its half-life to about one week, enabling once-weekly dosing. The SUSTAIN trial program tested it in type 2 diabetes.

2017–2024

Diabetes, obesity, and heart disease

Ozempic (injectable, T2D) was approved in 2017, Rybelsus (oral) in 2019, and Wegovy (higher-dose, obesity) in 2021. The 2023 SELECT cardiovascular outcomes trial then showed it reduces heart attacks and strokes, leading to a 2024 cardiovascular label expansion.

Clinical Trial Evidence

SUSTAIN program (Type 2 Diabetes)

Phase 3

N: Thousands across multiple trialsDuration: Up to 2 years

Consistent, robust HbA1c reductions and moderate weight loss, including superiority over other GLP-1 agonists and basal insulin in head-to-head comparisons. Basis for the Ozempic approval.

STEP 1 (Obesity, non-diabetic)

Phase 3

N: 1,961 adults with obesityDuration: 68 weeks

Mean weight reduction of −14.9% with semaglutide 2.4 mg vs −2.4% placebo — a landmark result that established GLP-1 therapy as a serious obesity treatment and the basis for Wegovy.

SELECT (Cardiovascular Outcomes)

Phase 3 CVOT

N: 17,604 adults with CV disease and obesity (no diabetes)Duration: ~3+ years

20% reduction in major adverse cardiovascular events (heart attack, stroke, CV death) — proving benefit beyond weight and glucose, and supporting the 2024 cardiovascular indication.

FLOW (Kidney Outcomes)

Phase 3

N: Adults with T2D and chronic kidney diseaseDuration: Stopped early for efficacy

Significant reduction in kidney disease progression and related death, expanding the evidence for organ-protective effects.

FDA Approval Process

Ozempic for type 2 diabetes (December 2017)

The SUSTAIN program supported FDA approval of injectable semaglutide as Ozempic for glycemic control in type 2 diabetes. Like all incretin-class drugs, it carries a boxed warning for thyroid C-cell tumors based on rodent studies.

Rybelsus oral (September 2019) & Wegovy (June 2021)

Rybelsus became the first oral GLP-1 (an absorption-enhancing formulation) for diabetes. Then, using the STEP trials, the higher-dose Wegovy was approved for chronic weight management — a separate brand and indication.

Cardiovascular label expansion (2024)

The SELECT outcomes trial allowed the FDA to expand labeling to reduce cardiovascular events in adults with established heart disease and obesity — an example of how a CVOT can transform a drug from metabolic to cardioprotective.

Mechanism of Action

GLP-1 receptor agonism

Semaglutide mimics GLP-1, binding its receptor to stimulate glucose-dependent insulin secretion from the pancreas — meaning it boosts insulin mainly when blood sugar is elevated, lowering hypoglycemia risk compared with insulin or sulfonylureas.

Glucagon suppression & gastric emptying

It suppresses inappropriate glucagon release and slows gastric emptying, which blunts post-meal glucose spikes and prolongs the feeling of fullness after eating.

Central appetite regulation

GLP-1 receptors in the hypothalamus and brainstem regulate appetite and reward. Semaglutide acts on these centers to reduce hunger and food cravings — the primary driver of its weight-loss effect.

Long half-life by design

Fatty-acid acylation lets semaglutide bind albumin and resist enzymatic breakdown, giving it a ~1-week half-life. This steady exposure underlies once-weekly injectable dosing and smoother appetite control.

Downstream Effects

Known / Documented

Robust HbA1c reduction in type 2 diabetes
~15% mean weight loss in obesity (STEP 1)
20% reduction in major cardiovascular events (SELECT)
Slowed kidney disease progression (FLOW)
Gastrointestinal side effects: nausea, vomiting, diarrhea, constipation
Boxed warning for thyroid C-cell tumors; risks of pancreatitis, gallbladder disease, and (in late-stage research) gastroparesis-like delayed emptying

Speculative / Under Study

Reduced cravings for alcohol, nicotine, and other addictive behaviors (active research)
Neuroprotection and reduced Alzheimer's risk (EVOKE trials underway)
Potential benefit in MASH/fatty liver disease
Possible cardiovascular benefit in heart failure with preserved ejection fraction
Concerns about muscle and bone loss during rapid weight loss require ongoing study
Weight regain after discontinuation is common — long-term therapy is typically required